Cancer immunotherapy comes of age
Ira Mellman, George Coukos, Glenn Dranoff · Nature · 2011
Cited by 3,875 works. doi:10.1038/nature10673
Authors
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome